The trial, sponsored by Istanbul Medipol University Hospital, explores a novel combination of metabolic cofactors aimed at improving cognitive and motor functions in AD and PD patients. Given the increasing prevalence of these neurodegenerative diseases, successful outcomes could position this therapy favorably in a competitive market that includes established treatments and emerging therapies. The combination approach may offer a differentiated product profile, appealing to both patients and healthcare providers. Further, the collaboration with industry partners like ScandiBio Therapeutics AB suggests potential for commercialization and broader market access. Diligence should focus on the safety profile and efficacy data to assess market entry viability and reimbursement potential.